[钾离子竞争性酸阻滞剂：最新进展]
[Potassium-competitive acid blockers: state of the art].
作者信息
Urrego José Augusto, Otero William, Cedrón Hugo, Marulanda Hernando, Piscoya Alejandro, Frías-Ordoñez Juan Sebastián, Otero Lina
机构信息
Servicio de Gastroenterología, Universidad Nacional de Colombia, Bogotá, Colombia.
Profesor de Gastroenterología, Hospital Universitario Nacional de Colombia, Bogotá, Colombia; Centro de Gastroenterología y Endoscopia, Bogotá, Colombia.
出版信息
Rev Gastroenterol Peru. 2025 Jan-Mar;45(1):38-55.
Potassium-competitive acid blockers (PCABs) constitute an emerging class of drugs for the treatment of acid-related disorders. They represent an alternative to proton pump inhibitors (PPIs), which have been the standard therapy but present certain limitations. Currently, PCABs are available in Latin America and offer a promising therapeutic option. This review compares both drug classes across various key aspects. Potassium-competitive acid blockers (PCABs) offer significant advantages over proton pump inhibitors (PPIs) in terms of speed of action, potency, and duration of acid suppression, as well as efficacy in the treatment of erosive esophagitis and Helicobacter pylori eradication, among other aspects. Additionally, they exhibit lower interindividual variability. Currently, PCABs are available in Latin America and represent a promising therapeutic option. This review compares both drug classes across various key aspects.
钾离子竞争性酸阻滞剂（PCABs）是一类新兴的用于治疗酸相关性疾病的药物。它们是质子泵抑制剂（PPIs）的替代药物，质子泵抑制剂一直是标准疗法，但存在一定局限性。目前，PCABs在拉丁美洲有供应，提供了一个有前景的治疗选择。本综述在各个关键方面对这两类药物进行了比较。钾离子竞争性酸阻滞剂（PCABs）在作用速度、效力、抑酸持续时间以及治疗糜烂性食管炎和根除幽门螺杆菌的疗效等方面，相对于质子泵抑制剂（PPIs）具有显著优势。此外，它们表现出较低的个体间变异性。目前，PCABs在拉丁美洲有供应，是一个有前景的治疗选择。本综述在各个关键方面对这两类药物进行了比较。
Zotero 插件